Back to Search
ROBERT GUNBY, MD
MD
Obstetrics & Gynecology Physician
NPI: 1891788790IndividualAccepts Medicare
Specialties, Licenses & Credentials
Obstetrics & Gynecology PhysicianPrimary
Obstetrics & Gynecology
Code: 207V00000X
E3296(TX)
CMS Specialties
PrimaryOBSTETRICS/GYNECOLOGY
Education
MEDICAL COLLEGE OF GEORGIA SCHOOL OF MEDICINE
Class of 1971
Research & Publications (13)
Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
PMID 18367480·Haematologica·2008
7-preclinical
A mechanistic design principle for protein tyrosine kinase sensors: application to a validated cancer target.
PMID 18085786·Org Lett·2008
8-other
Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.
PMID 18070884·J Biol Chem·2008
8-other
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy.
PMID 18045055·Anticancer Agents Med Chem·2007
6-review
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.
PMID 17537995·Blood·2007
7-preclinical
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
PMID 16970400·J Med Chem·2006
8-other
An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase.
PMID 15996942·Haematologica·2005
7-preclinical
Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.
PMID 15948671·Expert Opin Ther Targets·2005
6-review
Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity.
PMID 15938644·Biochemistry·2005
8-other
Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo.
PMID 14656879·Blood·2004
7-preclinical
Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
PMID 12681968·Haematologica·2003
7-preclinical
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.
PMID 12573349·Lancet Oncol·2003
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 4224 SWISS AVE
DALLAS, TX 75204 - Phone
- (214) 821-9938
Quick Facts
- NPI
- 1891788790
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 55
- Publications
- 13
Are you this provider?
Claim Your Profile